Lilly updates 2024 revenue to ~$45B, Q4 ~$13.5B; guides 2025 revenue $58-61B

ELI LILLY & Co

2024-FY EPS reported $11.71 revenue$45,042,700,000

2024 full-year revenue expected ~$45.0B, up 32% YoY and $4B above initial guidance midpoint.
Q4 2024 revenue ~$13.5B, up 45% YoY, but $400M below low end of Oct 30 guidance due to slower incretin growth and lower channel inventory.
Mounjaro Q4 revenue ~$3.5B, Zepbound ~$1.9B; non-incretin revenue grew 20% YoY.
2025 revenue guidance $58-61B, midpoint growth of 32% vs expected 2024; includes new product launches and manufacturing expansion.
Full Q4 2024 results and 2025 financial guidance to be reported on February 6, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.